UNSPSC 51112706: Satraplatin

This classification denotes a platinum compound with the molecular formula C6H13N.2C2H3O2.2Cl. Pt.H3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8D7B37T28G, chemically known as platinum, bis(acetato-o)amminedichloro(cyclohexanamine)-, (oc-6-43)- but more generally known as satraplatin, which bears US NIH Compound Identifier 123974. European Medicines Agency schedules Satraplatin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04333MIG.

UNSPSC 51112706 Satraplatin is a Commodity code naming a specific pharmaceutical active pharmaceutical ingredient used in cancer treatment. State and local governments do not appear to procure satraplatin directly under this code. The code is designed for federal pharmaceutical procurement, clinical trial supply chains, and research institutions rather than state and local health systems, which typically source oncology drugs through group purchasing organizations, prime vendors, or established pharmaceutical wholesalers governed by different procurement rules. No recent state or local contract opportunities are documented under this code.

The absence of activity under UNSPSC 51112706 at the state and local level reflects the procurement structure for specialty pharmaceuticals: state Medicaid programs, county health departments, and municipal hospitals source cancer medications through established GPO contracts, formulary agreements, or direct manufacturer relationships rather than open competitive bidding by UNSPSC code. This code should not be pursued as a state and local procurement target.